Health Insurance · NYSE: CI
Cigna Group earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 4 Feb 2027
Latest: Q3 2026
Cigna launched Health Sense, advanced its fee-based Signature pharmacy model toward a January 2027 start, and reported a strong 2027 selling season with 250+ new pharmacy clients.
Cigna launched Health Sense, a customer support model that starts with oncology and connects medical, pharmacy and benefit information so clinical teams can step in earlier. Specialty pharmacy kept gaining from lower-cost biosimilars and generics, with generic Revlimid adoption near 90%, while the pharmacy benefit business absorbed large client renewals. Employer demand held up: medical customers grew 2%, led by small-business Select clients, and the 2027 pharmacy selling season is tracking strong.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $65.6B * |
| Q1 2025 | $65.5B |
| Q2 2025 | $67.2B |
| Q3 2025 | $69.7B |
| Q4 2025 | $72.5B * |
| Q1 2026 | $68.5B |
| Q2 2026 | $71.7B |
| Q3 2026 | $73.7B |
Data
| Q1 2025 | $4.85 |
| Q2 2025 | $5.71 |
| Q3 2025 | $6.98 |
| Q1 2026 | $6.26 |
| Q2 2026 | $6.29 |
| Q3 2026 | $5.47 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 3.3% |
| Q1 2025 | 3.0% |
| Q2 2025 | 3.4% |
| Q3 2025 | 3.7% |
| Q4 2025 | 3.2% |
| Q1 2026 | 3.4% |
| Q2 2026 | 3.7% |
| Q3 2026 | 3.3% |
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $65.6Bd | $65.5B | $67.2B | $69.7B | $72.5Bd | $68.5B | $71.7B | $73.7B |
| Operating income | $2.2Bd | $2.0B | $2.3B | $2.6B | $2.3Bd | $2.4B | $2.7B | $2.4B |
| Operating margin | 3.3% | 3.0% | 3.4% | 3.7% | 3.2% | 3.4% | 3.7% | 3.3% |
| Net income | $1.5Bd | $1.3B | $1.5B | $1.9B | $1.2Bd | $1.7B | $1.7B | $1.4B |
| Diluted EPS | — | $4.85 | $5.71 | $6.98 | — | $6.26 | $6.29 | $5.47 |
| Operating cash flow | $5.2Bd | $1.9B | -$1.9Bd | $3.4Bd | $6.1Bd | $1.1B | -$421.0Md | $2.6Bd |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 5 Nov 202610-Q for the period ended 30 Sep 2026SEC ↗
- 30 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 30 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 26 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 30 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 31 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 2 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 27 Feb 202510-K for the period ended 31 Dec 2024SEC ↗